Treatment of vitiligo with a chimeric monoclonal antibody to  CD 20: a pilot study | Zendy

RuizArgüelles A. | Zendy; GarcíaCarrasco M. | Zendy; JimenezBrito G. | Zendy; SánchezSosa S. | Zendy; PérezRomano B. | Zendy; GarcésEisele J. | Zendy; CamachoAlarcón C. | Zendy; ReyesNúñez V. | Zendy; SandovalCruz M. | Zendy; MendozaPinto C. | Zendy; LópezColombo A. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of vitiligo with a chimeric monoclonal antibody to CD 20: a pilot study

Author(s) -

RuizArgüelles A.,

GarcíaCarrasco M.,

JimenezBrito G.,

SánchezSosa S.,

PérezRomano B.,

GarcésEisele J.,

CamachoAlarcón C.,

ReyesNúñez V.,

SandovalCruz M.,

MendozaPinto C.,

LópezColombo A.

Publication year - 2013

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.12168

Subject(s) - vitiligo , immunology , monoclonal antibody , medicine , monoclonal , virology , antibody , dermatology

Summary Five patients with active disseminated vitiligo were given 1 g of a chimeric (murine/human) monoclonal antibody to CD 20 in a single intravenous infusion and followed‐up for 6 months. Three of the patients showed an overt clinical and histological improvement of the disease, one presented slight improvement and the remaining patient showed no changes. Improvement was neither associated with changes in laboratory parameters nor to a specific human leucocyte antigen D‐related ( HLA ‐ DR) phenotype. We believe that these preliminary results are encouraging, and further clinical trials should be undertaken. An important aim should be the finding of a marker with a good response to this therapeutic approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research